Cargando…

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity

There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, David M, Staff, Matthew, Bain, Stephen C, Min, Thinzar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Touch Medical Media 2022
Materias:	Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354511/ https://www.ncbi.nlm.nih.gov/pubmed/35975210 http://dx.doi.org/10.17925/EE.2022.18.1.43

Ejemplares similares

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
por: Adams, Jessica M., et al.
Publicado: (2018)

The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
por: Yin, Win L., et al.
Publicado: (2020)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
por: Welling, Mila S., et al.
Publicado: (2021)

SUN-602 Weight Loss After Glucagon-Like Peptide-1 Receptor Agonist Treatment in Childhood Obesity with Diabetes and Cirrhosis Associated with a Homozygous MC4R Mutation
por: Klee, Philippe, et al.
Publicado: (2020)

Beneficial outcomes of glucagon like peptide-1 agonist therapy in a patient with Bardet Biedl syndrome and kidney transplant
por: Erturk, Banu, et al.
Publicado: (2023)

PSUN124 Weight Loss from Combination Anti-Obesity Medications Including Glucagon-Like Peptide-1 Receptors Agonists can Approach that Achieved from Bariatric Surgery
por: Bomberg, Eric M, et al.
Publicado: (2022)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014)

FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis
por: Silva, Caroliny Hellen, et al.
Publicado: (2023)

Hypothalamic Glucagon Receptors Regulate Feeding in Mice
por: Cunningham, Stephen E, et al.
Publicado: (2021)

Recent advances in understanding the role of glucagon-like peptide 1
por: Reed, Josh, et al.
Publicado: (2020)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes
por: Reddy Ankireddypalli, Anvitha, et al.
Publicado: (2023)

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
por: Yazıcı, Dilek, et al.
Publicado: (2022)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
por: Thompson, Aiysha, et al.
Publicado: (2016)

Effects of local authority expenditure on childhood obesity
por: Liu, Dan, et al.
Publicado: (2019)

Traditional Sunchang Gochujang Attenuates Obesity in High-Fat Diet Induced Obese Mice
por: Song, Jeong Woo, et al.
Publicado: (2022)

Obesity Paradox Does Exist
por: Hainer, Vojtech, et al.
Publicado: (2013)

Preclinical Efficacy of INST3399, a Synthetic Novel PKCbeta Inhibitor, for the Treatment of Obesity and Fatty Liver Disease
por: Mehta, Kamal
Publicado: (2022)

A map of community-based obesity prevention initiatives in Australia following obesity funding 2009–2013
por: Whelan, Jillian, et al.
Publicado: (2015)

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
por: Viljoen, Adie, et al.
Publicado: (2023)

Obesity and Mortality in a Pooled Analysis of Three Prospective Cohorts of Korean Adults: Is Obesity Paradox the BMI Paradox?
por: Jang, Hajin, et al.
Publicado: (2022)

The prevalence of general obesity, abdominal obesity, and hypertension and its related risk factors among young adult students in Bangladesh
por: Ali, Nurshad, et al.
Publicado: (2022)

Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
por: Araki, Eiichi, et al.
Publicado: (2022)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

Blenderized Watermelon Consumption Improves BMI, BMI Percentile, Body Fat, and A1C in Overweight or Obese Children
por: Daughtry, Jaikko, et al.
Publicado: (2022)

Activin Receptor-Like Kinase 7 Suppresses Lipolysis to Accumulate Fat in Obesity Through Downregulation of Peroxisome Proliferator–Activated Receptor γ and C/EBPα
por: Yogosawa, Satomi, et al.
Publicado: (2013)

Cholinergic Regulation of Ghrelin and Peptide YY Release May Be Impaired in Obesity
por: Maier, Christina, et al.
Publicado: (2008)

Defending the Con Side: Obesity Paradox Does Not Exist
por: Standl, Eberhard, et al.
Publicado: (2013)

Friendly Fat Theory – Explaining the Paradox of Diabetes and Obesity
por: Singla, Rajiv, et al.
Publicado: (2019)

Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
por: Anandhakrishnan, Ananthi, et al.
Publicado: (2016)

Equine glucagon-like peptide-1 receptor physiology
por: Kheder, Murad H., et al.
Publicado: (2018)

Using NIH-ADOPT Process to Characterize Adolescents with Obesity and Prediabetes
por: Arce, Britney, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rlf5sthq534cpcpnh8venjjc54